US2010184859A1PendingUtilityA1

Medicament having promoting action on hepatocyte proliferation

49
Assignee: JOSAI UNIVERSITY EDUCATIONAL CPriority: Jun 21, 2007Filed: Jun 20, 2008Published: Jul 22, 2010
Est. expiryJun 21, 2027(~0.9 yrs left)· nominal 20-yr term from priority
Inventors:Masahiko OgiharaMitsutoshi KimuraNaoto IshibashiJun Kojima
A61P 43/00A61P 35/00A61K 31/745A61P 1/16
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient.

Claims

exact text as granted — not AI-modified
1 . A medicament for promoting proliferation of hepatocytes, which comprises a polyprenyl compound as an active ingredient. 
   
   
       2 . A medicament for promoting liver regeneration, which comprises a polyprenyl compound as an active ingredient. 
   
   
       3 . The medicament according to  claim 2 , which is used for promoting liver regeneration in therapeutic treatment of hepatoma. 
   
   
       4 . The medicament according to  claim 3 , which is used for promoting liver regeneration after resection of hepatoma. 
   
   
       5 . The medicament according to  claim 1 , wherein the polyprenyl compound is a polyprenylcarboxylic acid. 
   
   
       6 . The medicament according to  claim 5 , wherein the polyprenylcarboxylic acid is 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid. 
   
   
       7 . The medicament according to  claim 5 , wherein the polyprenylcarboxylic acid is (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid. 
   
   
       8 . The medicament according to  claim 2 , wherein the polyprenyl compound is a polyprenylcarboxylic acid. 
   
   
       9 . The medicament according to  claim 3 , wherein the polyprenyl compound is a polyprenylcarboxylic acid. 
   
   
       10 . The medicament according to  claim 4 , wherein the polyprenyl compound is a polyprenylcarboxylic acid. 
   
   
       11 . The medicament according to  claim 8 , wherein the polyprenylcarboxylic acid is 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid. 
   
   
       12 . The medicament according to  claim 9 , wherein the polyprenylcarboxylic acid is 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid. 
   
   
       13 . The medicament according to  claim 10 , wherein the polyprenylcarboxylic acid is 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid. 
   
   
       14 . The medicament according to  claim 8 , wherein the polyprenylcarboxylic acid is (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid. 
   
   
       15 . The medicament according to  claim 9 , wherein the polyprenylcarboxylic acid is (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid. 
   
   
       16 . The medicament according to  claim 10 , wherein the polyprenylcarboxylic acid is (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid.

Join the waitlist — get patent alerts

Track US2010184859A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.